Literature DB >> 26050592

Neurocognitive Function Following Therapy for Low-Grade Gliomas.

Mary Frances McAleer1, Paul D Brown2.   

Abstract

Low-grade gliomas (LGGs) are a heterogenous group of primary brain neoplasms that most commonly occur in children and young adults, characterized by a slow, indolent course and overall favorable prognosis. Standard therapies used to treat LGGs have included surgical resection, radiotherapy, chemotherapy, or a combination thereof. Given the anticipated long survival and typical young age of patients with LGG, the long-term sequelae of therapy require special attention, especially as they affect neurocognitive function and quality of life. We review the complex interplay of baseline and treatment-related factors that perturb neurocognition as well as the effect of each treatment modality on altering neurocognitive outcomes in this patient population.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26050592     DOI: 10.1016/j.semradonc.2015.02.005

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  11 in total

1.  Long-term cognitive dysfunction after radiation therapy for primary brain tumors.

Authors:  Lene Haldbo-Classen; Ali Amidi; Lisa M Wu; Slavka Lukacova; Gorm von Oettingen; Hanne Gottrup; Robert Zachariae; Morten Høyer
Journal:  Acta Oncol       Date:  2019-02-13       Impact factor: 4.089

Review 2.  Controversies in the Therapy of Low-Grade Gliomas.

Authors:  Ivan D Carabenciov; Jan C Buckner
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

3.  Working memory training for adult glioma patients: a proof-of-concept study.

Authors:  Sarah Ellen Braun; Farah J Aslanzadeh; Autumn Lanoye; Stephanie Fountain-Zaragoza; Mark G Malkin; Ashlee R Loughan
Journal:  J Neurooncol       Date:  2021-09-07       Impact factor: 4.130

4.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Authors:  Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

5.  Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary utility in adult neuro-oncology.

Authors:  Ashlee R Loughan; Sarah E Braun; Autumn Lanoye
Journal:  Neurooncol Pract       Date:  2018-12-08

6.  Subjective executive dysfunction in patients with primary brain tumors and their informants: relationships with neurocognitive, psychological, and daily functioning.

Authors:  Sarah Ellen Braun; Autumn Lanoye; Farah J Aslanzadeh; Ashlee R Loughan
Journal:  Brain Inj       Date:  2021-12-07       Impact factor: 2.311

7.  Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma.

Authors:  M Back; M LeMottee; C Crasta; D Bailey; H Wheeler; L Guo; T Eade
Journal:  Radiat Oncol       Date:  2017-03-02       Impact factor: 3.481

8.  Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients-An Analysis Within the EORTC 22033 Clinical Trial.

Authors:  Jaap Jaspers; Alejandra Mèndez Romero; Mischa S Hoogeman; Martin van den Bent; Ruud G J Wiggenraad; Martin J B Taphoorn; Danielle B P Eekers; Frank J Lagerwaard; Anna Maria Lucas Calduch; Brigitta G Baumert; Martin Klein
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

9.  Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.

Authors:  Ingo K Mellinghoff; Timothy F Cloughesy; Marta Penas-Prado; Katherine B Peters; Howard A Burris; Elizabeth A Maher; Filip Janku; Gregory M Cote; Macarena I de la Fuente; Jennifer L Clarke; Benjamin M Ellingson; Saewon Chun; Robert J Young; Hua Liu; Sung Choe; Min Lu; Kha Le; Islam Hassan; Lori Steelman; Shuchi S Pandya; Patrick Y Wen
Journal:  Clin Cancer Res       Date:  2021-06-02       Impact factor: 13.801

10.  Long-term cognitive deficits in pediatric low-grade glioma (LGG) survivors reflect pretreatment conditions-report from the German LGG studies.

Authors:  Thomas Traunwieser; Daniela Kandels; Franz Pauls; Torsten Pietsch; Monika Warmuth-Metz; Brigitte Bison; Juergen Krauss; Rolf-Dieter Kortmann; Beate Timmermann; Ulrich-Wilhelm Thomale; Peggy Luettich; Anne Neumann-Holbeck; Tanja Tischler; Pablo Hernáiz Driever; Olaf Witt; Astrid K Gnekow
Journal:  Neurooncol Adv       Date:  2020-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.